Pfizer reported Phase 2b data for the once‑monthly GLP‑1 acquired in its $10 billion Metsera deal, showing clinically meaningful weight loss in obesity patients and supporting a broad Phase 3 plan with higher doses. The company said monthly maintenance dosing produced sustained weight reductions through 28 weeks, prompting a larger, dose‑escalated pivotal program this year. The update arrived alongside a separate financial disclosure: Pfizer took a $4.4 billion impairment charge tied to a cancer asset, part of a wider pipeline pruning and portfolio realignment disclosed on the company’s earnings call. Management said pruning is largely complete and resources will be reallocated to prioritized programs, including the Metsera asset and other near‑term catalysts.